BioTuesdays

Category - Markets

Shockwave Medical
Markets

Canaccord starts ShockWave Medical at buy; PT $39

Canaccord Genuity initiated coverage of ShockWave Medical (NASDAQ:SWAV) with a “buy” rating and $39 price target. The stock closed at $33.47 on March 29. Analyst Jason Mills writes that ShockWave’s technology –...

April 1, 2019
Proteon Therapeutics
Markets

Maxim cuts Proteon Therapeutics to hold; removes PT

Maxim Group downgraded Proteon Therapeutics (NASDAQ:PRTO) to “hold” from “buy” and withdrew its previous $5 price target after the company’s second Phase 3 study of vonapanitase failed to reach statistical significance...

March 28, 2019
Eye Point Logo
Markets

EyePoint Pharma prices $20-million stock offering

EyePoint Pharmaceuticals (NASDAQ:EYPT) priced a public offering of 10,526,500 of its common shares at a price of $1.90 each to raise about $20-million. EyePoint also granted underwriters a 30-day option to purchase up...

March 28, 2019
Fate Therapeutics
Markets

SVB Leerink starts Fate Therapeutics at OP; PT $20

SVB Leerink launched coverage of Fate Therapeutics (NASDAQ:FATE) with an “outperform” rating and $20 price target. The stock closed at $16.71 on March 27. Analyst Daina Graybosch writes that Fate is at the forefront of...

March 28, 2019
Affimed
Markets

SVB Leerink starts Affimed at OP; PT $8

SVB Leerink initiated coverage of Affimed NV (NASDAQ:AFMD) with an “outperform” rating and $8 price target. The stock closed at $4.17 on March 27. “Our positive view is fuelled by the potential of the company’s novel...

March 28, 2019
Atossa Genetics
Markets

Maxim ups Atossa Genetics PT to $9 from $5

Maxim Group raised its price target for Atossa Genetics (NASDAQ:ATOS) to $9 from $5 after the Institutional Review Board approved the use of oral endoxifen as a post-mastectomy treatment in pre-menopausal, estrogen...

March 26, 2019
Conatus
Markets

Roth cuts Conatus Pharma to neutral with PT of $1.70

Roth Capital Partners downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “neutral” with a price target of $1.70 after the company’s ENCORE-NF trial failed to meet its primary endpoint of an improvement of fibrosis...

March 26, 2019
Recro Pharma
Markets

Roth cuts Recro Pharma to neutral with PT $7.50

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an...

March 25, 2019
Nevro
Markets

Canaccord ups Nevro PT to $62 from $46

Canaccord Genuity raised its price target for Nevro (NYSE:NVRO) to $62 from $46 after the medical device maker appointed Keith Grossman as president and CEO, effective immediately. The stock closed at $44.77 on March 19...

March 20, 2019
INmune Bio
Markets

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

March 19, 2019